Is The Tide Turning For Sarepta?

Will heart insurers pay for Sarepta Therapeutic ’s ( SRPT ) Exondys 51? That’s a question that several analysts have weighed on today. It appears that payors are still actively evaluating and reevaluating coverage of the Duchenne muscular dystrophy drug Exondys 51.